Jongeun Rhee1, Erikka Loftfield2, Neal D Freedman2, Linda M Liao2, Rashmi Sinha2, Mark P Purdue1. 1. Division of Cancer Epidemiology and Genetics, Occupational and Environmental Epidemiology Branch, National Cancer Institute, Rockville, MD, USA and. 2. Division of Cancer Epidemiology and Genetics, Metabolic Epidemiology Branch, National Cancer Institute, Rockville, MD, USA.
Abstract
BACKGROUND: Coffee consumption has been associated with a reduced risk of some cancers, but the evidence for renal cell carcinoma (RCC) is inconclusive. We investigated the relationship between coffee and RCC within a large cohort. METHODS: Coffee intake was assessed at baseline in the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Among 420 118 participants eligible for analysis, 2674 incident cases were identified. We fitted Cox-regression models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for coffee consumption vs non-drinkers. RESULTS: We observed HRs of 0.94 (95% CI 0.81, 1.09), 0.94 (0.81, 1.09), 0.80 (0.70, 0.92) and 0.77 (0.66, 0.90) for usual coffee intake of <1, 1, 2-3 and ≥4 cups/day, respectively (Ptrend = 0.00003). This relationship was observed among never-smokers (≥4 cups/day: HR 0.62, 95% CI 0.46, 0.83; Ptrend = 0.000003) but not ever-smokers (HR 0.85, 95% CI 0.70, 1.05; Ptrend = 0.35; Pinteraction = 0.0009) and remained in analyses restricted to cases diagnosed >10 years after baseline (HR 0.65, 95% CI 0.51, 0.82; Ptrend = 0.0005). Associations were similar between subgroups who drank predominately caffeinated or decaffeinated coffee (Pinteraction = 0.74). CONCLUSION: In this investigation of coffee and RCC, to our knowledge the largest to date, we observed a 20% reduced risk for intake of ≥2 cups/day vs not drinking. Our findings add RCC to the growing list of cancers for which coffee consumption may be protective. Published by Oxford University Press on behalf of the International Epidemiological Association 2021. This work is written by US Government employees and is in the public domain in the US.
BACKGROUND: Coffee consumption has been associated with a reduced risk of some cancers, but the evidence for renal cell carcinoma (RCC) is inconclusive. We investigated the relationship between coffee and RCC within a large cohort. METHODS: Coffee intake was assessed at baseline in the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Among 420 118 participants eligible for analysis, 2674 incident cases were identified. We fitted Cox-regression models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for coffee consumption vs non-drinkers. RESULTS: We observed HRs of 0.94 (95% CI 0.81, 1.09), 0.94 (0.81, 1.09), 0.80 (0.70, 0.92) and 0.77 (0.66, 0.90) for usual coffee intake of <1, 1, 2-3 and ≥4 cups/day, respectively (Ptrend = 0.00003). This relationship was observed among never-smokers (≥4 cups/day: HR 0.62, 95% CI 0.46, 0.83; Ptrend = 0.000003) but not ever-smokers (HR 0.85, 95% CI 0.70, 1.05; Ptrend = 0.35; Pinteraction = 0.0009) and remained in analyses restricted to cases diagnosed >10 years after baseline (HR 0.65, 95% CI 0.51, 0.82; Ptrend = 0.0005). Associations were similar between subgroups who drank predominately caffeinated or decaffeinated coffee (Pinteraction = 0.74). CONCLUSION: In this investigation of coffee and RCC, to our knowledge the largest to date, we observed a 20% reduced risk for intake of ≥2 cups/day vs not drinking. Our findings add RCC to the growing list of cancers for which coffee consumption may be protective. Published by Oxford University Press on behalf of the International Epidemiological Association 2021. This work is written by US Government employees and is in the public domain in the US.
Authors: Saverio Caini; Giovanna Masala; Calogero Saieva; Marina Kvaskoff; Isabelle Savoye; Carlotta Sacerdote; Oskar Hemmingsson; Bodil Hammer Bech; Kim Overvad; Anne Tjønneland; Kristina E N Petersen; Francesca Romana Mancini; Marie-Christine Boutron-Ruault; Iris Cervenka; Rudolf Kaaks; Tilman Kühn; Heiner Boeing; Anna Floegel; Antonia Trichopoulou; Elisavet Valanou; Maria Kritikou; Giovanna Tagliabue; Salvatore Panico; Rosario Tumino; H B As Bueno-de-Mesquita; Petra H Peeters; Marit B Veierød; Reza Ghiasvand; Marko Lukic; José Ramón Quirós; Maria-Dolores Chirlaque; Eva Ardanaz; Elena Salamanca Fernández; Nerea Larrañaga; Raul Zamora-Ros; Lena Maria Nilsson; Ingrid Ljuslinder; Karin Jirström; Emily Sonestedt; Timothy J Key; Nick Wareham; Kay-Tee Khaw; Marc Gunter; Inge Huybrechts; Neil Murphy; Konstantinos K Tsilidis; Elisabete Weiderpass; Domenico Palli Journal: Int J Cancer Date: 2017-03-09 Impact factor: 7.396
Authors: Susan M Gapstur; Rebecca L Anderson; Peter T Campbell; Eric J Jacobs; Terryl J Hartman; Janet S Hildebrand; Ying Wang; Marjorie L McCullough Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-07-27 Impact factor: 4.254
Authors: Lena Maria Nilsson; Ingegerd Johansson; Per Lenner; Bernt Lindahl; Bethany Van Guelpen Journal: Cancer Causes Control Date: 2010-05-30 Impact factor: 2.506
Authors: Frances E Thompson; Victor Kipnis; Douglas Midthune; Laurence S Freedman; Raymond J Carroll; Amy F Subar; Charles C Brown; Matthew S Butcher; Traci Mouw; Michael Leitzmann; Arthur Schatzkin Journal: Public Health Nutr Date: 2007-07-05 Impact factor: 4.022